Sabine Hutchison is Co-CEO and Co-Founder of Seuss+, and has spent over two decades inside clinical development — as a scientist, a data leader, and now a governance partner for biotech and pharma programs. These perspectives examine the structural patterns that decide whether a clinical program holds together under pressure: how vendor-sponsor partnerships actually function, where governance quietly breaks down, and why most oversight failures are visible in the operating model long before they appear on a timeline.
The through-line across this work is simple. Clinical program outcomes are not primarily a function of protocol complexity or site performance. They are a function of the leadership choices made before a single patient is enrolled: how vendors are selected, how escalation is defined, how data ownership is structured, and whether the sponsor is equipped to ask the questions that a CRO will not volunteer. Sabine writes for clinical operations leaders, biotech executives, and sponsor governance teams who are making those choices in real time, usually with incomplete information and compressed timelines.
Key takeaways from these perspectives
- Most CRO underperformance is visible in the governance model before it ever shows up in the data.
- Vendor selection is a leadership decision, not a procurement exercise. The wrong structure guarantees the wrong outcome.
- Data ownership clauses quietly decide who controls the narrative when a trial hits trouble.
- Sponsor-side oversight fails when escalation paths are informal. It holds when they are contractual.
- The sponsors who avoid late-stage surprises are the ones who invest in partnership integrity early, not the ones who react faster.
Trials don't fail at the site. They fail at the partnership.
Vendor selection is a leadership decision
Most sponsor organizations treat CRO selection as a procurement workflow: scope the work, solicit bids, score the responses, sign the MSA. That framing is the first leadership failure. A CRO is not a line item. It is the operating system through which an entire clinical program will be delivered, and the selection process is the only moment the sponsor holds genuine structural leverage. The questions asked before signature determine what can be asked after. The teams that get this right treat vendor selection as a governance decision with procurement support, not the other way around, and they staff it accordingly.
Read more: CRO selection beyond the RFP.
Governance is the oversight model, not the status call
Weekly status calls are not governance. Governance is the contractual and operational structure that decides who sees what data, who escalates, who has decision rights, and how disagreements are resolved before they become delays. When sponsors describe a CRO relationship as “collaborative” without being able to name the escalation ladder, the governance model does not exist, and the trial is running on goodwill. Goodwill is a fine lubricant and a terrible load-bearing structure. It holds until the first difficult conversation, at which point the absence of defined rights and paths becomes the problem everyone has to solve while also trying to stay on timeline.
Read more: The governance gap nobody audits.
Data ownership is a trust architecture
Who owns the data, who can access it in real time, and who controls the reporting cadence are not technical questions. They are trust questions with contractual answers. The sponsors who get this right build visibility into the MSA itself: independent access to the EDC, clear rules on source data verification, defined timelines for safety signal reporting, and an explicit right to audit the operating layer without a six-week lead time. The sponsors who discover they cannot independently verify their own trial data are usually discovering it during a regulatory inspection, which is the worst possible moment to renegotiate the relationship.
Read more: Data ownership and partnership integrity.
Partnership integrity is the leading indicator
Every late-stage clinical surprise — enrollment miss, data quality issue, regulatory setback — has a pre-history inside the sponsor-vendor relationship. Partnership integrity is the leading indicator that is almost never measured: whether the two sides are solving the same problem, whether bad news travels fast, whether the incentives are aligned past the next milestone payment. Sponsors who build this into their operating rhythm do not get fewer problems; they see them earlier, which is almost the same thing. Earlier visibility is where all the value is. By the time a problem is visible in a monthly dashboard, the options for solving it cleanly are already closing.
Read more: Partnership integrity as a leading indicator.
The industry backdrop
These perspectives sit inside a development environment that has become harder, not easier, over the last decade. Trials are larger, protocols are more complex, regulatory expectations are more granular, and the pool of sites and investigators capable of running them is not expanding fast enough to match demand. The numbers below frame why the leadership-level choices Sabine writes about are not academic — they compound across every program a sponsor runs.
Frequently asked questions
About these perspectives
Sabine Hutchison is Co-CEO and Co-Founder of Seuss+, a clinical development partner firm based in Hamburg, Germany. She has spent over two decades in clinical development as a scientist, data leader, and governance advisor to biotech and pharma sponsors.
Sabine writes about the structural patterns inside clinical development that decide program outcomes: vendor selection, governance design, data ownership, and partnership integrity between sponsors and CROs.
Biotech and pharma leaders making vendor and governance decisions. That means heads of clinical operations, development leaders, sponsor executives, and boards overseeing clinical-stage programs.
Roughly one long-form essay per month, plus occasional shorter pieces responding to industry events or regulatory developments.
Yes. Sabine accepts a limited number of speaking and podcast engagements each year on clinical governance, vendor-sponsor trust, and leadership under clinical pressure. Requests go through the media page.